SUTRO BIOPHARMA, INC. Operating Cash Flow
SUTRO BIOPHARMA, INC. (STRO) reported Operating Cash Flow of -$80.55 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-12
- SUTRO BIOPHARMA, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$38.29M.
- SUTRO BIOPHARMA, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$42.26M.
- SUTRO BIOPHARMA, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$26.43M.
- SUTRO BIOPHARMA, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$38.19M.
- SUTRO BIOPHARMA, INC. net cash provided by (used in) operating activities for fiscal 2025 was -$177.23M.
- SUTRO BIOPHARMA, INC. net cash provided by (used in) operating activities for fiscal 2024 was -$191.54M.
- SUTRO BIOPHARMA, INC. net cash provided by (used in) operating activities for fiscal 2023 was -$111.62M, a 3245.00% decline from fiscal 2022.
- SUTRO BIOPHARMA, INC. net cash provided by (used in) operating activities for fiscal 2022 was $3.55M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$38.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$80.55M 10-Q · filed 2026-08-12 | -$106.98M derived: sum of 3 quarters · filed 2026-08-12 | -$145.17M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | -$42.26M 10-Q · filed 2026-05-14 | -$68.69M derived: sum of 2 quarters · filed 2026-05-14 | -$106.88M derived: sum of 3 quarters · filed 2026-05-14 | -$151.61M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | -$26.43M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | -$64.62M derived: sum of 2 quarters · filed 2026-03-23 | -$109.35M derived: sum of 3 quarters · filed 2026-08-12 | -$177.23M 10-K · filed 2026-03-23 |
| 2025-09-30 | -$38.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$82.91M derived: sum of 2 quarters · filed 2026-08-12 | -$150.80M 10-Q · filed 2025-11-06 | -$222.53M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | -$44.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$112.61M 10-Q · filed 2026-08-12 | -$184.34M derived: sum of 3 quarters · filed 2026-08-12 | -$248.86M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | -$67.88M 10-Q · filed 2026-05-14 | -$139.62M derived: sum of 2 quarters · filed 2026-05-14 | -$204.14M derived: sum of 3 quarters · filed 2026-05-14 | -$194.68M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | -$71.74M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | -$136.25M derived: sum of 2 quarters · filed 2026-03-23 | -$126.80M derived: sum of 3 quarters · filed 2026-03-23 | -$191.54M 10-K · filed 2026-03-23 |
| 2024-09-30 | -$64.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$55.06M derived: sum of 2 quarters · filed 2025-11-06 | -$119.80M 10-Q · filed 2025-11-06 | -$105.73M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $9.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$55.29M 10-Q · filed 2025-08-07 | -$41.21M derived: sum of 3 quarters · filed 2025-08-07 | -$74.72M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$64.74M 10-Q · filed 2025-05-08 | -$50.67M derived: sum of 2 quarters · filed 2025-05-08 | -$84.17M derived: sum of 3 quarters · filed 2025-05-08 | -$115.37M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $14.07M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | -$19.43M derived: sum of 2 quarters · filed 2025-03-13 | -$50.63M derived: sum of 3 quarters · filed 2025-03-13 | -$111.62M 10-K · filed 2025-03-13 |
| 2023-09-30 | -$33.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$64.70M derived: sum of 2 quarters · filed 2024-11-13 | -$125.69M 10-Q · filed 2024-11-13 | -$149.55M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-06-30 | -$31.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$92.19M 10-Q · filed 2024-08-13 | -$116.05M derived: sum of 3 quarters · filed 2025-03-13 | -$50.20M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-03-31 | -$60.99M 10-Q · filed 2024-05-13 | -$84.86M derived: sum of 2 quarters · filed 2025-03-13 | -$19.00M derived: sum of 3 quarters · filed 2025-03-13 | -$22.19M derived: sum of 4 quarters · filed 2025-03-13 |
| 2022-12-31 | -$23.86M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $41.99M derived: sum of 2 quarters · filed 2025-03-13 | $38.80M derived: sum of 3 quarters · filed 2025-03-13 | $3.55M 10-K · filed 2025-03-13 |
| 2022-09-30 | $65.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $62.67M derived: sum of 2 quarters · filed 2023-11-13 | $27.41M 10-Q · filed 2023-11-13 | $5.83M derived: sum of 4 quarters · filed 2024-03-25 |
| 2022-06-30 | -$3.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$38.44M 10-Q · filed 2023-08-10 | -$60.02M derived: sum of 3 quarters · filed 2024-03-25 | -$84.43M derived: sum of 4 quarters · filed 2024-03-25 |
| 2022-03-31 | -$35.26M 10-Q · filed 2023-05-15 | -$56.84M derived: sum of 2 quarters · filed 2024-03-25 | -$81.24M derived: sum of 3 quarters · filed 2024-03-25 | -$86.50M derived: sum of 4 quarters · filed 2024-03-25 |
| 2021-12-31 | -$21.58M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | -$45.99M derived: sum of 2 quarters · filed 2024-03-25 | -$51.25M derived: sum of 3 quarters · filed 2024-03-25 | -$81.68M 10-K · filed 2024-03-25 |
| 2021-09-30 | -$24.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$29.67M derived: sum of 2 quarters · filed 2022-11-08 | -$60.10M 10-Q · filed 2022-11-08 | -$78.98M derived: sum of 4 quarters · filed 2023-03-30 |
| 2021-06-30 | -$5.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | -$35.69M 10-Q · filed 2022-08-08 | -$54.57M derived: sum of 3 quarters · filed 2023-03-30 | -$72.26M derived: sum of 4 quarters · filed 2023-03-30 |
| 2021-03-31 | -$30.43M 10-Q · filed 2022-05-09 | -$49.31M derived: sum of 2 quarters · filed 2023-03-30 | -$67.00M derived: sum of 3 quarters · filed 2023-03-30 | -$79.50M derived: sum of 4 quarters · filed 2023-03-30 |
| 2020-12-31 | -$18.88M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | -$36.57M derived: sum of 2 quarters · filed 2023-03-30 | -$49.07M derived: sum of 3 quarters · filed 2023-03-30 | -$67.80M 10-K · filed 2023-03-30 |
| 2020-09-30 | -$17.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$30.19M derived: sum of 2 quarters · filed 2021-11-10 | -$48.92M 10-Q · filed 2021-11-10 | -$62.08M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | -$12.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | -$31.23M 10-Q · filed 2021-08-09 | -$44.39M derived: sum of 3 quarters · filed 2022-02-28 | -$60.51M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | -$18.73M 10-Q · filed 2021-05-07 | -$31.89M derived: sum of 2 quarters · filed 2022-02-28 | -$48.01M derived: sum of 3 quarters · filed 2022-02-28 | -$63.61M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | -$13.16M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$29.28M derived: sum of 2 quarters · filed 2022-02-28 | -$44.88M derived: sum of 3 quarters · filed 2022-02-28 | -$65.02M 10-K · filed 2022-02-28 |
| 2019-09-30 | -$16.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | -$31.72M derived: sum of 2 quarters · filed 2020-11-05 | -$51.87M 10-Q · filed 2020-11-05 | -$57.80M derived: sum of 4 quarters · filed 2021-03-18 |
| 2019-06-30 | -$15.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | -$35.75M 10-Q · filed 2020-08-06 | -$41.68M derived: sum of 3 quarters · filed 2021-03-18 | $5.89M derived: sum of 4 quarters · filed 2021-03-18 |
| 2019-03-31 | -$20.14M 10-Q · filed 2020-05-11 | -$26.08M derived: sum of 2 quarters · filed 2021-03-18 | $21.49M derived: sum of 3 quarters · filed 2021-03-18 | $7.55M derived: sum of 4 quarters · filed 2021-03-18 |
| 2018-12-31 | -$5.93M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18 | $41.64M derived: sum of 2 quarters · filed 2021-03-18 | $27.69M derived: sum of 3 quarters · filed 2021-03-18 | $12.68M 10-K · filed 2021-03-18 |
| 2018-09-30 | $47.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | $33.63M derived: sum of 2 quarters · filed 2019-11-08 | $18.62M 10-Q · filed 2019-11-08 | $13.78M derived: sum of 4 quarters · filed 2020-03-16 |
| 2018-06-30 | -$13.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | -$28.95M 10-Q · filed 2019-08-14 | -$33.79M derived: sum of 3 quarters · filed 2020-03-16 | |
| 2018-03-31 | -$15.01M 10-Q · filed 2019-05-15 | -$19.85M derived: sum of 2 quarters · filed 2020-03-16 | ||
| 2017-12-31 | -$4.84M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | -$37.07M 10-K · filed 2020-03-16 | ||
| 2017-09-30 | -$32.23M 10-Q · filed 2018-11-14 | |||
| 2016-12-31 | -$13.15M 10-K · filed 2019-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 |